Skip to main content
Equibles

ANL · Adlai Nortye Group Ltd.

Track ANL — free

Use ANL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.12 +0.48 (+4.52%)
Rebalance outlook locked
Market Cap
$740.58M
Shares
64.40M
Volume · Oct 21 532.6K Avg daily vol (3M) 216.23K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.26 Open$10.80 Day$10.80–11.68 52W close$0.88–16.60 Avg vol 30d280K Short int4.4M · 6.8% float · 38.2d Short vol50% DataSep 2023–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-714.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+544.8%
Trailing year
Short interest
6.8%
Latest settlement · 38.2 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −21%
below
RSI (14) 38
neutral
MACD trend Negative
52-week position 66%
mid-range
Momentum
relative strength
Weak
1-month return −29%
trailing
6-month return −21%
trailing
YTD return +693%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+62% holders QoQ · +22 funds added
Insider flow Distributing
Net -$411.1K over 90 days · 100% sells
Short interest Falling
6.84% of float · ▼ -0.5% MoM · 38.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
42 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 154%
annualized · 1-yr
Max drawdown −47%
past year
ATR 11.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−21% Bearish
RSI (14)
38 Neutral
MACD trend
Negative Bearish
52-week position
66% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+62% holders QoQ · +22 funds added
Insider flow Distributing
Net -$411.1K over 90 days · 100% sells
Short interest Falling
6.84% of float · ▼ -0.5% MoM · 38.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
42 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $11 · 66% Range high $17
vs 200-day avg +2% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANL
Adlai Nortye Group Ltd.
this stock
$740.58M +693.0% — — 6.8%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +15.7% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $96.65B +733.5% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.4% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.22B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
42
% held
41.1%
Net QoQ
+14.9M sh
Top holder
Cormorant Asset Managemen…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
4.4M
Days to cover
38.2d
Change
-20.6K sh
View
Short Volume
Short vol %
50%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
154
Value
$2.4K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
39.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$411.1K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 15, 2026
This year
16

Adlai Nortye Group Ltd. entered trial collaboration and supply agreements with Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035 alone and with cetuximab in a global Phase I trial; both will supply cetuximab at no cost.

View
Proposed Sales
Value
$1.2M
Shares
80.0K
Filed
Sep 18, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 16, 2026
Last webcast
Sep 14, 2026
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
ANL +3.5% -28.5% -21.1% -29.6% +693.0%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY +3.0% -29.2% -28.7% -31.0% +679.6%
Key facts CIK 1944552 CUSIP 00704R109 Visit website Investor relations